The following video is part of our "Motley Fool Conversations" series, in which, Eric Bleeker, senior technology editor, and James Early, advisor, discuss topics around the investing world.

In today's edition, James suggests that dividend-focused investors look toward Johnson & Johnson. While there's been a high degree of pessimism surrounding the company as it's faced product recalls and other product missteps, James says the company is essentially a "mutual fund for the health-care industry" and has been unfairly beaten down.

Eric Bleeker owns no shares of the companies listed above. James Early and The Motley Fool own shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Pfizer and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.